Opinion|Videos|December 9, 2024 (Updated: December 6, 2024)
Biomarkers and Therapeutic Impact on PIRA
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Biomarkers of PIRA in MS are essential for understanding disease mechanisms and guiding treatment strategies.
- Inflammatory signatures in cerebrospinal fluid and peripheral blood offer insights into PIRA's pathophysiology.
Panelists discuss how recent investigations into progression independent of relapse activity (PIRA) in multiple sclerosis (MS) have revealed complex inflammatory signatures in cerebrospinal fluid and peripheral blood, with biomarkers like neurofilament light chain and pro-inflammatory cytokines showing promise in tracking neurodegeneration. The Swedish MS Registry’s findings suggest that early implementation of high-efficacy disease-modifying therapies may effectively delay or prevent PIRA progression, though these results require further robust, multicenter validation to definitively establish clinical significance and generalizability.
Advertisement
Video content above is prompted by the following:
- What is our understanding of biomarkers of PIRA? What do we know about inflammatory signatures in the cerebrospinal fluid and peripheral blood of patients with PIRA?
- Findings from the Swedish MS Registry show that early use of high vs medium efficacy disease-modifying therapy may be effective in delaying or preventing PIRA. Are these differences meaningful? Do you have any concerns about this study?
Advertisement
Related to this article
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
4
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
5